ALN-SOD / Alnylam, Regeneron 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ALN-SOD / Alnylam, Regeneron
NCT06351592: First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

Recruiting
1
42
Canada, Japan
ALN-SOD, Diluent, Placebo (PB)
Regeneron Pharmaceuticals
Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene
04/29
04/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ALN-SOD / Alnylam, Regeneron
NCT06351592: First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

Recruiting
1
42
Canada, Japan
ALN-SOD, Diluent, Placebo (PB)
Regeneron Pharmaceuticals
Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene
04/29
04/29

Download Options